FAQs

Anti-Parkinson Drugs Global Market Report 2022 – By Drugs Class (Levodopa/Carbidopa, Dopamine Receptor Agonists, Monoamine Oxidase Type B (MAO-B) Inhibitors, Catechol-O-Methyltransferase (COMT)-inhibitors, Anticholinergics), By Route of Administration (Oral, Injection, Transdermal), By Distribution Channel (Hospital Pharmacies, Retailer Pharmacies, Online Pharmacies) – Market Size, Trends, And Global Forecast 2022-2026

What is the definition of the anti-parkinson drugs market?

The anti-parkinson drugs market consists of sales of drugs used for treating Parkinson's disease (PD), generated by the establishments that manufacture these drugs. Parkinson's disease is a neurodegenerative disorder that affects predominately dopaminergic neurons in a specific area of the brain named substantia nigra and disturbs the movement of the body. People suffering from PD may experience tremor, bradykinesia, limb rigidity, gait, and balance problems.

How will the anti-parkinson drugs market drivers and restraints affect anti-parkinson drugs market dynamics? What forces will shape the anti-parkinson drugs industry going forward?

The anti-parkinson drugs market growth is aided by increasing geriatric population and surging cases of parkinson's disease (PD). However, some anti-Parkinson drugs market restraints include increasing investments by governments and companies for parkinson’s disease drug R&D

What is the forecast market size of the anti-parkinson drugs market?

The anti-parkinson drugs market forecast is expected to reach $7.78 billion in 2025 at a compound annual growth rate of 9%.

How is the anti-parkinson drugs market segmented?

The global anti-Parkinson drugs market is segmented -
1) By Drugs Class: Levodopa/Carbidopa, Dopamine Receptor Agonists, Monoamine Oxidase Type B (MAO-B) Inhibitors, Catechol-O-Methyltransferase (COMT)-inhibitors, Anticholinergics, Other Drugs .
2) By Route of Administration: Oral, Injection, Transdermal.
3) By Distribution Channel: Hospital Pharmacies, Retailer Pharmacies, Online Pharmacies.

Which region has largest share, and what is the market size and growth by geography according to the anti-parkinson drugs global market report?

For more detail on this, request a sample here.

Who are the key players of the global anti-parkinson drugs market?

Top competitors in the anti-parkinson drugs market are GlaxoSmithKline plc, Pfizer, Merck, Novartis, Roche, UCB S.A, Teva Pharmaceuticals, AbbVie Inc., Mylan, Boehringer Ingelheim, Orion Pharma, ACADIA Pharmaceuticals Inc, Sun Pharma, Wockhardt, Dr. Reddy

What are the key trends in the global anti-parkinson drugs market?

Major trends influencing the anti-parkinson drugs market include increasing investments by governments and companies for Parkinson’s disease drug R&D.

What are the major opportunities in the anti-parkinson drugs market and the approaches companies can take to take advantage of them?

For detail on the future and current opportunities in the global anti-parkinson drugs market, request a sample here

How does the anti-parkinson drugs market relate to the overall economy and other similar markets?

For this and further detailed insights on the market, request a sample here.